Search results
Results from the WOW.Com Content Network
[4] Menotropin preparations are designed for use in selected women where they stimulate the ovaries to mature follicles, thus making them more fertile. They are administered by typically daily injection, intramuscularly or subcutaneously, for about ten days under close supervision to adjust dose and duration of therapy.
Urofollitropin is a purified form of follicle-stimulating hormone (FSH) that is manufactured by extraction from human urine and then purified [1] to remove various proteins and other substances.
In men: Used to treat select cases of Hypogonadotropic Hypogonadism in adult males. [25] In off-label use, some urologists prescribe hCG in low doses in combination with testosterone replacement to preserve fertility. [26] In male children: Also used to treat prepubertal cryptorchidism not due to anatomical obstruction.
ATC code G03 Sex hormones and modulators of the genital system is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
This is a list of investigational sex-hormonal agents, or sex-hormonal agents that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
The median effective dose is the dose that produces a quantal effect (all or nothing) in 50% of the population that takes it (median referring to the 50% population base). [6] It is also sometimes abbreviated as the ED 50, meaning "effective dose for 50% of the population". The ED50 is commonly used as a measure of the reasonable expectancy of ...
Opioids have antigonadotropic effects and can reduce luteinizing hormone and testosterone levels in men. [ 11 ] [ 12 ] [ 13 ] A 2015 systematic review and meta-analysis found that opioid therapy decreased testosterone levels in men by about 165 ng/dL (5.7 nmol/L) on average, which was a reduction in testosterone level of almost 50%. [ 11 ]
[202] [4] The bioavailability of MPA with oral administration is approximately 100%. [4] A single oral dose of 10 mg MPA has been found to result in peak MPA levels of 1.2 to 5.2 ng/mL within 2 hours of administration using radioimmunoassay. [202] [203] Following this, levels of MPA decreased to 0.09 to 0.35 ng/mL 12 hours post-administration.